Skip to main content

Table 1 Patient characteristics

From: Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs

 

IMPROVED (N = 104)

RETRO (N = 57)

Age, mean years (SD)

49 (13)

55 (13)

Female, n (%)

67 (64%)

37 (65%)

BMI, mean (SD)

25 (4)

25 (4)

Ever smoker, n (%)

47 (46%)

18 (32%)

Disease duration, median (IQR)

19 (9–36) weeks^

5 (3–10) years

Anti-CCP2 IgG positive, n (%)

85 (83%)

34 (62%)

RF IgM positive, n (%)

79 (79%)

39 (68%)

Current DMARD use

 Methotrexate

104 (100%)

47 (82%)

 Glucocorticoids

0 (0%)

11 (19%)

 Other csDMARDS

0 (0%)

6 (11%)

 Biological DMARDs

0 (0%)

21 (37%)

 Etanercept

5 (9%)

 Adalimumab

6 (11%)

 Tocilizumab

5 (9%)

 Golimumab

2 (4%)

 Certolizumab

3 (5%)

DAS44 at tapering/stopping moment, mean (SD)

0.9 (0.4)

DAS28-ESR at tapering/stopping moment, mean (SD)

1.8 (0.7)

Disease flare within 12 months

78 (75%)

26 (46%)

Calprotectin (ng/mL), median (IQR)

1000 (230–2422)

1000 (650–2000)

  1. SD standard deviation, IQR interquartile range, Anti-CCP2 anti-citrullinated protein 2 antibody, RF rheumatoid factor, cs/bDMARD conventional synthetic/biological disease-modifying antirheumatic drugs, DAS disease activity score, ESR erythrocyte sedimentation rate
  2. ^Disease duration is based on the moment of study inclusion; in the IMPROVED study, this excludes the first 4 months of treatment
  3. Categories are not mutually exclusive
  4. Patients received sulfasalazine (n = 2), hydroxychloroquine (n = 2), leflunomide (n = 1), or azathioprine (n = 1)